載入中
NASDAQHealthcareMedical - Diagnostics & Research
最新資料
US$63.67
+US$1.465 · +2.36%
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
前收盤價
US$63.67
+US$1.465 · +2.36%
盤中時間採用ET。市場資料可能有所延遲。
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
日內區間
目前US$63.67
52週區間
目前US$63.67
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
賣出
估值
8
估值過高
情緒
57
多空交錯
風險
56
風險偏高
動能
70
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
日內區間
目前US$63.67
52週區間
目前US$63.67
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3.8億 USD | 3.34億 USD | 2.8億 USD | 3.22億 USD | 2.96億 USD |
| 銷貨成本 | 1.23億 USD | 1.1億 USD | 1.02億 USD | 1.12億 USD | 9738.9萬 USD |
| 毛利 | 2.57億 USD | 2.24億 USD | 1.78億 USD | 2.1億 USD | 1.99億 USD |
| 研究與開發 | 7142.9萬 USD | 7240.5萬 USD | 8186.6萬 USD | 9038.8萬 USD | 7652.5萬 USD |
| 銷售、一般及管理費用 | 2.1億 USD | 2.06億 USD | 2.01億 USD | 1.96億 USD | 1.52億 USD |
| 營業費用 | 2.82億 USD | 1.83億 USD | 3.82億 USD | 2.87億 USD | 2.29億 USD |
| 利息收入 | 917.4萬 USD | 1176.5萬 USD | 1186.7萬 USD | 376.2萬 USD | 16萬 USD |
| 折舊和攤銷 | 2041.6萬 USD | 1975.7萬 USD | 1982.4萬 USD | 1600.7萬 USD | 1188.5萬 USD |
| 營業利益 | −2507.1萬 USD | 4076.5萬 USD | −2.03億 USD | −7723.1萬 USD | −2972.6萬 USD |
| 淨利 | −2135.4萬 USD | 5254.9萬 USD | −1.9億 USD | −7661.3萬 USD | −3066.2萬 USD |
公司資料更新於 2026年10月11日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$62.25
下跌空間 2.23%報告持有此股票曝險的交易所交易基金。
ARK Genomic Revolution ETFARKG8487.26萬4.14%15.57億 USD0.75%US$51.30+4.08%
iShares Russell 2000 ETFIWM8408.67萬0.11%787.4億 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI8329.77萬0.84%98.74億 USD0.35%US$153.77+3.00%
Vanguard Morningstar Total Stock Market ETFVTI7798.97萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF3009.54萬0.03%954億 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO2946.96萬0.21%139.17億 USD0.24%US$356.78+0.94%
Dimensional - US Small Cap ETFDFAS2482.44萬0.07%338.69億 USD0.31%US$78.35+0.32%
iShares Biotechnology ETFIBB2280.95萬0.22%108.2億 USD0.44%US$206.49+3.00%ARK Genomic Revolution ETFARKGiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWODimensional - US Small Cap ETFDFASiShares Biotechnology ETFIBBAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
